Alivus Life Sciences enterprise value

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY24Mar 2024FY23Mar 2023FY22Mar 2022
1,012301284512
Reference items — trailing FY values
2,6842,2832,1612,123
923674642616
840621600578
—414313598
285285143465
—284143465
—129170132
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ALIVUS₹1,397.40

Alivus Life Sciences Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABAARTIDRUGSAKUMSAGARWALEYEAPLLTDADVENZYMESAARTIPHARMCORONA
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
Current/LTM
TTM · last close
- Cash, Equiv & ST Investments512.2283.8301.41,011.6
Reference Items — Trailing FY Values
Sales2,123.22,161.22,283.22,684.4
EBITDA616.1642.3674.2922.7
EBIT578.2600.2620.8840.4
Operating Cash Flow597.6313.4413.5—
Free Cash Flow465.4143.2284.5284.5
FCFF (free cash flow to the firm)465.4143.1284.2—
Capital Expenditure132.2170.2129.0—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.